Nintedanib receives positive CHMP opinion for second-line treatment
Nintedanib*, when added to docetaxel, is the first lung cancer treatment to have provided over one year overall survival for patients with advanced adenocarcinoma, after first-line chemotherapy.09/29/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Kidney Cancer | Lung Cancer | Taxotere | Urology & Nephrology